Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00005804 · ClinicalTrials.gov registry record · Phase 2

Bone Marrow Transplantation in Treating Patients With Hematologic Cancer

A Phase 2 study of Lymphoma and Leukemia, sponsored by Fred Hutchinson Cancer Center.

Completed
Registry status
Phase 2
Development phase
1
Study location

NCT00005804 is a Phase 2 study of Lymphoma and Leukemia that has completed, run by Fred Hutchinson Cancer Center. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00005804, a Phase 2 study of Lymphoma and Leukemia, has completed, sponsored by Fred Hutchinson Cancer Center.

COMPLETED
Registry status
Phase 2
Development phase
1
Study location

Study Summary

RATIONALE: Radiation therapy uses high-energy x-rays to damage cancer cells. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with bone marrow transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of bone marrow transplantation in treating patients who have hematologic cancer.

Interventions

  • DRUG cyclophosphamide
  • RADIATION radiation therapy
  • PROCEDURE allogeneic bone marrow transplantation

Study Locations (1)

Washington

  • Fred Hutchinson Cancer Research Center - Seattle

Trial Details

FieldValue
Start Date 1999-10
Est. Completion 2002-08
Phase Phase 2

Sponsor

Fred Hutchinson Cancer Center

483 total trials

What the Registry Record Tells You About NCT00005804

The ClinicalTrials.gov registry entry for NCT00005804 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Fred Hutchinson Cancer Center, which has 483 total studies on file at ClinicalTrials.gov.

The record links to 7 conditions, with Lymphoma appearing as the primary indexed condition, and to 3 interventions - of which cyclophosphamide is the first listed.

NCT00005804 reports 1 study location spanning 1 distinct geographic area - top geographies include Washington.

Frequently Asked Questions

What is clinical trial NCT00005804 about?

NCT00005804 is a clinical study titled "Bone Marrow Transplantation in Treating Patients With Hematologic Cancer". RATIONALE: Radiation therapy uses high-energy x-rays to damage cancer cells. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with bone marrow transplantation may allow the doctor to give higher doses of chemotherapy...

What is the current status of trial NCT00005804?

This trial is currently completed. It is a Phase 2 study. The study started on 1999-10. Estimated completion is 2002-08.

What conditions does trial NCT00005804 study?

This clinical trial studies the following conditions: Lymphoma, Leukemia, Myelodysplastic Syndromes, Multiple Myeloma and Plasma Cell Neoplasm, Chronic Myeloproliferative Disorders.

What interventions are being tested in trial NCT00005804?

The interventions under investigation include: cyclophosphamide (DRUG), radiation therapy (RADIATION), allogeneic bone marrow transplantation (PROCEDURE).

Who is sponsoring clinical trial NCT00005804?

This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00005804 being conducted?

This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.